Clinical Therapeutic Effect Evaluation In The Treatment Of Heat Syndrome In The Lung And Stomach Of Sepsis With Qingbugongxia Prescription

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16009140

Enrollment

Unknown

Registered

2016-09-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

The Experimental Group:Qingbugongxia Prescription

The Control Group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Sepsis; 2. Accorded with diagnostic criteria of Heat Syndrome In The Lung And Stomach; 3. Course of disease: <72h; 4. Aged 18~75 years, male or female; 5. APACHEII 14~25; 6. Having signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Transplantation recipents; 2. Unexplained gastrointestinal tract bleeding, megacolon leading to bleeding, gastrointestinal tract surgery within half a year,serious haemorrhoids,serious cirrhosis; 3. Suffering mental illness; 4. Coexistent blood diseases, cancer, autoimmune disease,or using autoimmune disease inhibitors; 5. Allergic body or allergic to drug; 6. Pregnant or breast feeding women; 7. Attending other clinical observation at the same time;

Design outcomes

Primary

Measure	Time frame
Blut-Routine-Untersuchung;Biochemical Test of Finger Blood;Myocardial Enzyme;Coagulation Indicator;Blood Gas Analysis;Blood Lactic Acid;Endotoxin;	—

Countries

China

Contacts

Public ContactDongqiang Wang

Tianjin First Central Hospital

wdqklm@sina.com+86 13032211655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026